Suven Life drug candidate clears toxic tests; stock up
Suven Life Sciences clinical drug candidate SUVN- 502, meant for treatment of Alzheimer’s disease and Schizophrenia, has successfully completed regulatory toxic studies in animals with high margin of safety.
By ET Bureau |
MUMBAI: Suven Life Sciences clinical drug candidate SUVN- 502, meant for treatment of Alzheimer’s disease and Schizophrenia, has successfully completed regulatory toxic studies in animals with high margin of safety. These studies are essential for FDA approval to initiate human phase 2a clinical trials.
The potential market opportunity for the drug is more than $20 billion annually.
The stock was at day’s high at Rs 21.20, up 4.95 per cent on the BSE. It touched a low of Rs 20.20 in early trade.
The potential market opportunity for the drug is more than $20 billion annually.
The stock was at day’s high at Rs 21.20, up 4.95 per cent on the BSE. It touched a low of Rs 20.20 in early trade.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
